- Home
- Equipment
- usa new york
- immune cells
Show results for
Refine by
Immune Cells Equipment Supplied In Usa New York
17 equipment items found
by:ALPHA-1 BIOLOGICS LLC based inSTONY BROOK, NEW YORK (USA)
Alpha-1 Biologics has developed orally-available small molecules including our lead molecule, Alpha-101. We have shown that Alpha-101 is safe and effective in mice for increasing immune cells. When combined with the PD-1 immune checkpoint inhibitor, Alpha-101 significantly decreases the growth of kidney tumors in mice. ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociHum is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models. Through genetic humanizations, VelociHum mice have been optimized to allow for better development of human immune cells in vivo, as well as to allow for engraftment of ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TFF2 is a small, secreted protein, encoded by the TFF2 gene in humans that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, Hemogenyx Pharmaceuticals developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. CDX antibodies belong to a class of bi-specific antibodies that ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-Immune are cells that have been induced with tumor necrosis factor alpha (TNF-a) and interferon-gamma (IFN-g), to transiently alter their secretion profile. The product has been evaluated in pre-clinical studies and a peer-reviewed article in the journal Scientific Reports, from Nature, was published which examined the effect of the cells in ...
Manufactured by:BlueRock Therapeutics based inCambridge, MASSACHUSETTS (USA)
With our cell+gene platform, BlueRock is aiming to redefine the very way we treat disease, moving from addressing mere symptoms to restoring health lost to cell damage or degeneration. Instead of prescribing a pill to treat tremors in patients with Parkinson’s, we might restore the chemical messengers that were destroyed, addressing tremors at the source. ...
Manufactured by:Profacgen based inShirley, NEW YORK (USA)
Recombinant Cynomolgus PDCD1 Protein (B0LAJ3) (Leu 25 - Gln 167) with a polyhistidine tag at the C-terminus was expressed in ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to ...
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated delivery platform based on arenaviruses, a family of naturally-occurring ...
Manufactured by:Protara Therapeutics, Inc. based inNew York, NEW YORK (USA)
TARA-002 is an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan by Chugai Pharmaceutical Co., ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Originally developed for in-house testing, the company’s Advanced peripheral blood Hematopoietic Chimera (“ApbHC”) is a novel type of humanised mouse that presents several advantages over existing mouse models. It has applications for disease modelling and drug development, and potentially for ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
Our DeltEx platform has enabled a deep pipeline of preclinical and clinical product candidates, which are designed to effectively target and potentially eradicate disease, to improve patient ...
Manufactured by:Scopus BioPharma based inNew York, NEW YORK (USA)
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the activity of the STAT3 gene by way of RNA interference. CO-sTiRNA™ also stimulates TLR9 receptors to activate the ...